NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering

NRx Pharmaceuticals has announced the completion of its registered direct offering for 9,670,002 shares of common stock at $0.65 per share, resulting in gross proceeds of approximately $6.28 million before deducting placement agent fees and other expenses. The company intends to use net proceeds from the offering for working capital and general corporate purposes, as well as potentially using it..